Adverse events, side effects and complications in mesenchymal stromal cell-based therapies
Stem Cell Investigation · 2022-11 · 9 · 7-7
DOI: 10.21037/sci-2022-025 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Stem Cell Investigation, 2022-11. Verfasst von Denis S Baranovskii und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Obninsk, Russia. Die Arbeit wurde bisher 146-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Patientensicherheit
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, Obninsk, Russia.
- Peoples' Friendship University of Russia (RUDN University), Moscow, Russia.
- Obninsk Institute for Nuclear Power Engineering of the National Research Nuclear University MEPhI, Obninsk, Russia.
Zitieren
APA
Baranovskii, D. S., Klabukov, I. D., Arguchinskaya, N. V., Yakimova, A. O., Kisel, A. A., Yatsenko, E. M., Ivanov, S. A., Shegay, P. V., & Kaprin, A. D. (2022). Adverse events, side effects and complications in mesenchymal stromal cell-based therapies. Stem Cell Investigation, 9, 7-7. https://doi.org/10.21037/sci-2022-025
Vancouver
Baranovskii DS, Klabukov ID, Arguchinskaya NV, Yakimova AO, Kisel AA, Yatsenko EM, et al. Adverse events, side effects and complications in mesenchymal stromal cell-based therapies. Stem Cell Investigation. 2022;9:7-7. doi:10.21037/sci-2022-025
BibTeX
@article{Baranovskii2022,
author = {Baranovskii, Denis S and Klabukov, Ilya D and Arguchinskaya, Nadezhda V and Yakimova, Anna O and Kisel, Anastas A and Yatsenko, Elena M and Ivanov, Sergei A and Shegay, Peter V and Kaprin, Andrey D},
title = {Adverse events, side effects and complications in mesenchymal stromal cell-based therapies},
journal = {Stem Cell Investigation},
year = {2022},
volume = {9},
pages = {7--7},
doi = {10.21037/sci-2022-025}
}
EUVIMED